about
Retinal sensitivity and retinal nerve fiber layer thickness measured by optical coherence tomography in glaucoma.Diagnostic validity of optic disc and retinal nerve fiber layer evaluations in detecting structural changes after optic neuritis.Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsThe Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors.Correlations Between the Individual Risk for Glaucoma and RNFL and Optic Disc Morphometrical Evaluations in Ocular Hypertensive Patients.Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study.Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis.Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyLatanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsImpact of recent legislative bills regarding clinical research on Italian ethics committee activity.KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis.Performance of imaging modalities in the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis.Malignant incidental extracardiac findings on cardiac CT: systematic review and meta-analysis.Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis.Diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced endoscopic ultrasound (ECEUS) for the differentiation of pancreatic lesions: a systematic review and meta-analysis.PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter?Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cIncidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?Health-related quality of life in patients with primary open-angle glaucoma. An Italian multicentre observational study.Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.Modified Radical Hysterectomy Versus Extrafascial Hysterectomy in the Treatment of Stage I Endometrial Cancer: Results From the ILIADE Randomized StudyVision-related quality of life and symptom perception change over time in newly-diagnosed primary open angle glaucoma patientsPharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapyHigh concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practicePredictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerDynamic contour tonometry and goldman applanation tonometry: correlation with intracameral assessment of intraocular pressurePredictive value of heidelberg retina tomograph parameters for the development of glaucoma in the European glaucoma prevention study
P50
Q33294580-E1242CB6-285D-48FB-B5BC-D1FF133FC03EQ33551861-40C71793-AA46-46FD-89F1-122BA79218FAQ34452900-84FAD0F7-5E9E-4C78-A404-C3278B416167Q34741660-9A6BB60B-0D51-4262-AB34-13EAA2860674Q35668773-7CD492C0-5639-44FE-9353-9D79F1952DF5Q35746271-E3696FD0-0FFC-4DC5-8691-497A960F45A8Q36145407-833D9579-DF4B-47FE-A6F8-29E5D51DC1CCQ36287562-3DF91769-5A11-43F0-A49E-83DB8773D323Q36545375-6120CED8-D455-4864-8CC3-C49026A5CF34Q37143748-56080825-0740-4882-973D-EA54665DDB29Q37283085-F0A3F214-1316-4E9F-BE78-84352DCF05E5Q37330719-93C39138-3107-4B79-9278-5C5AE1F2FECBQ37660982-5B40CFA6-5088-4B4F-AD03-0EB68ABE3C71Q38067277-E72B949C-4B5A-4F41-94E0-65D44F9070C9Q38130984-B7A0BAB1-F01B-48FB-AFAA-D55E5505CFB3Q38155442-C719DDE3-531E-4B54-9F5E-3DFE8E4D126EQ38250111-195CEA18-1401-4A3E-B235-53C8AC94ED64Q38956435-3C42B0CB-4412-4135-8372-3ABDFA619F80Q40829243-CA0463A3-8CD3-4C34-8673-21A0C3098965Q41548711-FCA9C865-984A-4F84-A194-A1F0800532B9Q41949668-F04A6F39-396E-472D-AF3F-9C2258412E48Q43223506-2225E760-7226-49C7-9623-B9CD6C103D6DQ46034442-6DB17306-9388-4F77-A676-B43ACE03438DQ46139364-81B49AFB-A2F1-473E-9A49-EFBAE6EF3907Q46207223-729C7E10-7D5D-4575-BE12-557FBE1FCBF9Q47732726-91D52832-9F3F-4A95-8863-3F6B676B935FQ47947730-6A4A0681-6816-4DAD-A688-94C66EAD1142Q50644888-F66CDDD8-B183-4E91-8B18-35728247C8B4Q51688636-820F5073-1459-4962-868E-4C38424AD0ECQ53487996-C981B0FD-2339-47C1-9B33-41175283B579Q53795029-AD0DFDEE-761E-417F-AFF5-0FD03D05330DQ54341358-5969F3CD-0999-428A-BAC3-A2C1C062323BQ57903482-63FCF3E0-A31D-4D21-A4C7-AD3BE5AC2367Q64077169-FF53C367-AE57-4E2C-A64F-6B81C91DD7B2Q80076968-A18993A1-5445-46F6-A5E6-19FDFA4A411FQ82839912-BF36F524-A280-410D-923B-E4F8317F896BQ83002002-702B3936-33D0-4336-ACC3-F3DA01CF7B5EQ83068132-CD46CC5E-A100-4DB1-98E1-A51B82258873Q85066190-08A81163-6C5E-452C-9546-044165CB0DE2Q86110139-4668FCB6-CE65-4F7C-86AE-09E09E6168E0
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1058-4137
@en
name
Eliana Rulli
@ast
Eliana Rulli
@en
Eliana Rulli
@es
Eliana Rulli
@nl
type
label
Eliana Rulli
@ast
Eliana Rulli
@en
Eliana Rulli
@es
Eliana Rulli
@nl
prefLabel
Eliana Rulli
@ast
Eliana Rulli
@en
Eliana Rulli
@es
Eliana Rulli
@nl
P106
P1153
23994365300
P31
P496
0000-0003-1058-4137